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ABSTRACT
Prostate cancer is the fourth most common type of non-skin malignancy in 
male malignancies. In Indonesia, the definitive data are unreported, however, 
Globocan reported prostate cancer in 5th place in 2018.  The aim of this study is 
to provide in updating database of prostate cancer profile in tertiary hospital in 
Indonesia. A retrospective study involving a total of 90 prostate cancer patients 
who underwent follow-up care at Dr. Sardjito General Hospital, Yogyakarta in 
the period of 2015 to 2020 was conducted. Data of the patients from their medical 
records consisted of age, gender, prostate volume, PSA level, testosterone level, 
hydronephrosis, TURP history. From a total 90 subjects, showed an average 
age of 67 years (SD=10.4). The level of prostate volume (TAUS), most subjects 
were >30 cm3 with 73 subjects (81.4%). Of the total subjets, the median of total 
PSA value for diagnosis is 234.4 (94.4 – 1720.3) ng/mL with the median of total 
testosterone value at diagnosis is 317 (10 -  384) ng/dL. An equal between biopsy 
and TURP were used in method of diagnosis and histologic finding consisting 
of Adenocarcinoma were found in 88 subjects (97.8%) with Gleason score > 7 in 
69 subject (69.6%) and ISUP Grade 5 in 59 subject (65.6%). The staging  T1c was 
found in 43 subjects (47.8%) and M staging with metastasis stage was found 
in 55 subjects (61.1%). In conclusion, most patients with prostate cancer are 
identified as adenocarcinoma with metastatic stage. In general, the prostate 
cancer patients age more than 61 years old with prostate volume (TAUS) > 30 
cm3. In addition, prostate volume and testosterone level can be routinely used 
as initial screening and periodic assessment to evaluate prognosis and disease 
progression.
ABSTRAK
Kanker prostat merupakan jenis keganasan non-kulit peringkat empat yang 
sering dijumpai pada pria. Di Indonesia, data yang pasti belum ada, tetapai 
Globacon melaporkan kanker prostat menempati peringkat lima tahun 2018. 
Diagnosis dan pengobatan dini kanker ini dapat menurunkan mortalitasnya. 
Peneltian ini bertujuan mengkaji profil kanker prostat di RSUP Dr. Sardjito, 
Yogyakarta. Penelitian retrospektif ini dilakukan terhadap 90 penderita kanker 
prostat yang menjalani perawatan di RSUP Dr. Sardjito selama kurun waktu 
2015 sampai 2020. Data penderita dari rekam medis yang meliputi umur, jenis 
kelamin, volume prostat, kadar PSA, kadar testoteron, hidronefrosis, riawyat 
TURP, hasi pemeriksaan histopatologi, skor Gleason, derajad ISUP dan tingkat 
TNM dikumpulan dalam penelitian ini. Rerata umur penderita adalah 67 
±10,4 tahun terdiri dari 22 (24.4%) berumur < 60 tahun, 34 (37.8%) penderita 
berumur 61-70 tahun dan 34 (37.8%) penderita berumur > 70 tahun. Hampir 
semua penderita (87 orang atau 97.8%) didiagnosis adenokarsinoma. Sebagian 
besar pasien (73 orang atau 81.4%) mempunyai volune prostat (TAUS) > 30 
cm3 dengan nilai tengah saat diagnosis 51 cm3 (38.3 – 104.4). Selanjutnya, 
nilai tengah PSA untuk diagnosis adalah 234.4 (94.4 – 1720.3) ng/mL dan nilai 
tengah kadar testoteron saat diagnosis adalah 317 (10 – 384) ng/dL. Dapat 
disimpulkan, sebagian besar penderita kanker prostat diidentifikasi sebagai 
adenokarsinoma dengan fase metastasis. Umumnya, penderita kanker prostat 
berumur lebih dari 61 tahun dengan volume prostat > 30 cm3. Selain itu, 
volume prostat dan kadar testoteron dapat digunakan secara rutin untuk 
skreening awal dan pemeriksaan rutin untuk mengevaluasi prognosis dan 
progresivitas penyakit.           
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INTRODUCTION
Prostate cancer is currently the 
most commonly diagnosed cancer in 
105 countries. It is the fourth most 
common type of non-skin malignancy 
(7.1%) in male malignancies, the 
second most common malignancy in 
males worldwide.1 In 2018, 1.3 million 
new cases of prostate cancer and 
359,000 related deaths worldwide were 
reported. With rapid population growth 
and aging worldwide, this cancer is 
the 5th leading cause of death in men.1 
Early diagnosis and early treatment of 
prostate cancer have been associated 
with reduced mortality rates in many 
countries, including the United States, 
North America, Oceania, Northern, and 
Western Europe as well as in developing 
countries in Asia.2-5 
The incidence and mortality of 
cancer are increasing rapidly throughout 
the world as diagnostic tools advance. As 
one of the diagnostic methods of choice, 
the prostate-specific antigen (PSA) is a 
member of the kallikrein gene family. It 
is also known as the androgen-dependent 
hK3 (human kallikrein 3).6-9 Screening for 
PSA in prostate cancer cases has reduced 
the death rate of prostate cancer by more 
than 40%, as well as the 75% decrease 
in the number of advanced cases since 
diagnosis in the United States.10
In Indonesia, there are no definite 
data, let alone in testosterone level or 
tumor burden data although Globocan 
reported that prostate cancer in the 5th 
place in Indonesia in 2018.1,11 Based on 
2011 data from the Indonesian Urological 
Oncology Society (ISUO) during the 2006-
2010 period, 971 patients were diagnosed 
with prostate cancer. The mean age 
was 68.3 years, mostly (37.6 %) at 70-
79 years of age. The diagnostic method 
used was primarily biopsied in 563 
cases (57.9%). The majority cases were 
patients with stage 4 (50.5%), followed 
by stage 2 (271 cases or 27.9 %), stage 1 
(83 cases or 8.5%), and stage 3 (28 cases 
or 2.9 %). Orchidectomy was the most 
widely used initial therapy (307 cases 
or 31%), followed by hormonal drugs 
(182 or 18%), radical prostatectomy (89 
cases or 9%), radiotherapy (63 cases or 
6%) and the rest was active monitoring, 
chemotherapy, and combinations.12 In 
this study, we reported  the profile of the 
prostate cancer in Dr. Sardjito General, 
Yogyakarta for a period of  5 years.
MATERIALS AND METHODS
Subjects and design
This was an observational study 
with descriptive retrospective design 
involving 90 prostate cancer patients 
who underwent follow-up treatment 
at the Dr. Sardjito General Hospital, 
Yogyakarta, Indonesia from 2015 to 2020.
Protocol of study
The data from patients’ medical 
records in Dr. Sardjito General Hospital, 
Yogyakarta were collected by 2 observers 
to reduce bias. This study has been 
approved by the Medical and Health 
Research Ethics Committee, Faculty of 
Medicine, Public Health, and Nursing, 
Universitas Gadjah Mada, Yogyakarta 
(Ref. No. KE/FK/1059/EC/2020). Inclusion 
criteria were patients who have been 
diagnosed with prostate cancer from 
2015 to 2020. Exclusion criteria were 
patients who were not registered in Dr. 
Sardjito General Hospital, Yogyakarta. 
The data of the patient’s age, gender, 
prostate volume, pre-treatment total PSA 
level, pre-treatment total testosterone 
level, hydronephrosis, TURP history, 
histopathology results, Gleason scores, 
ISUP grade, staging, and tumor burden 
were retrieved from the medical report.
Statistical analysis
Data were analyzed with cross 
tabulation table using the IBM SPSS 23.00 
statistics and served in table form.
243
Dany YA, et al., Prostate cancer profile ...
RESULTS
Ninety secondary data of prostate 
cancer inpatients visited and registered in 
Dr. Sardjito General Hospital, Yogyakarta 
from 2015 to 2020 were collected (TABLE 
1). According to the patient age, among 
90 patients, 22 patients (24.4%) were 
<60 y.o., 34 patients (37.8%) were 61-70 
y.o. and 34 patients (37.8%) were >70 
y.o. Average age of the patients were 67 
±10.4 y.o. Furthermore, according to the 
level of prostate volume (TAUS) showed 
most patients (48 patients or 53.3%) had 
prostate volume > 30 cm3 with median 
of 51 cm3 (38.3 – 104.4).  Median of the 
PSA level for diagnosis was 234.4 (94.4 
– 1720.3) ng/mL, whereas median of the 
testosterone level was 317 (10 - 384) ng/
dL.
Based on the histological findings 
(TABLE 1), adenocarcinoma was found in 
most of all patients (88 patients or 97.8%) 
with most of patients had Gleason score 
> 7 (69 patients 0r 69.6%) and ISUP grade 
> 2 (75 patients or 83%). In addition, 
staging ≤ T2 was found in 74 patients 
(82.2%) and metastasis stage was found 
in 55 subjects (61.1%).
TABLE 1. Characteristic of subjects
Characteristics n (%) Mean (SD) Median Q1 Q3
Age (y.o)
•	 60 22 (24.4) 67 ± 10.4 70 63.75 75
•	 61 – 70 34 (37.8)
•	 > 70 34 (37.8)
Prostate volume (cm3)
•	 ≤ 30 17 (18.6) 102 ± 117.5 51 38.3 104.4
•	 > 30 48 (53.3)
•	Unknown 31 (34.4)
Total PSA (ng/mL)
•	 ≤ 20 8 (8.9) 710 ± 1334.5 234.4 94.4 1720.3
•	 > 20 58 (64.4)
•	Unknown 24 (26.7)
Testosterone level (ng/dL)
•	 ≤ 300 19 (21.1) 280 ± 310 317 10 384













•	 ≤ 7 21 (23.3)
•	 > 7 69 (69.6)
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ISUP grade
•	 1 8 (8.9)
•	 2 6 (6.1)
•	 3 5 (5.6)
•	 4 10 (11.1)
•	 5 59 (59.6)
Staging
•	 ≤ T2 74 (82.2)







•	High volume 46 (51.1)
•	Low volume 23 (25.6)
•	Unknown 21 (23.3)
and decreases in advanced cases 
based on the EAU Risk Group.10,14 The 
majority of patients visiting Dr. Sardjito 
General Hospital, Yogyakarta have 
been diagnosed with locally advanced 
prostate cancer early on. It is believed 
that early diagnosis of metastatic stage 
prostate cancer is very likely and that 
further screening efforts are required 
to take into account the cost-benefit of 
early-stage prostate cancer diagnostics.
Interestingly, according to the 
researchers, although the screening of 
testosterone levels in cases of prostate 
cancer at the time of initial diagnosis 
with serum total testosterone levels 
had low levels.15 Androgen is the main 
source of the prostate to grow. Higher 
consumption of androgen leads to the 
increase of prostate hyperplasia, which 
can be seen by measuring PSA. Two 
studies showed low level of serum total 
Testosterone correlated with advanced 
diseases.16-17 Researchers assume that 
further research involving total serum 
testosterone levels with a larger sample 
may be able to further explain the 
androgen-dependent pathway and the 
accuracy of the management options 
for prostate cancer. Researchers assume 
DISCUSSION
The Indonesian Society of Urologic 
Oncology (ISUO) reported during the 
period of 2006 to 2010 971 patients were 
diagnosed with prostate cancer. The 
average age of the patients was 68.3 
years.12 Demographics of prostate cancer 
patients at Dr. Sardjito General Hospital 
during the period of  2015 to 2020 showed 
50% of cases were locally advanced 
prostate cancer, including high metastatic 
and high-volume Tumor Burden disease. 
This study also showed that  the majority 
of patients with      prostate cancers 
are only detected at an advanced stage 
or metastasis. Lack of knowledge of 
Indonesian people concerning prostate 
cancer and its screening test cause 
the delay in early diagnosis and not 
regularly performed. Metastatic tracking 
was mandatory based on the results of 
the data in this study. Cases of prostate 
cancer are of interest to researchers, 
where total serum testosterone levels 
may have reached castration levels at 
the time of initial diagnosis and without 
prior hormonal therapy.
PSA screening in cases of prostate 
cancer reduces the mortality rate 
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that metastatic tracking is mandatory, 
considering the results of this study, 
it was found that the majority of the 
initial presence of PSA in prostate 
cancer patients with total serum PSA 
levels >20 ng/mL was due to cost-benefit 
considerations.
CONCLUSION
In contrast with developed country, 
this study shows that most Indonesian 
prostate cancer patients are diagnosed 
in metastatic stage with higher PSA level 
and ISUP grade. Further encouragement 
in prostate cancer screening for men 
with symptoms or risk factor should be 
considered to find more cases in lower 
stages for better prognosis and survival 
rate. 
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